Fabry Disease Market Report 2026

Fabry Disease Market Overview

• Fabry Disease market size has reached to $2.26 billion in 2025 • Expected to grow to $3.27 billion in 2030 at a compound annual growth rate (CAGR) of 7.7% • Growth Driver: A Growing Focus On Personalized Medicine Fueling The Growth Of The Market Due To Improved Treatment Outcomes And Tailored Therapies • Market Trend: Reducing Immunogenic Responses In Enzyme Replacement Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Fabry Disease Market?

Fabry disease is a rare genetic disorder caused by a deficiency in the enzyme alpha-galactosidase A, leading to the accumulation of fat in the body's cells and organs. The purpose of treatment is to manage symptoms, reduce organ damage, and improve the quality of life for affected individuals. The main types of fabry disease are type 1, type 2, and other types. Type 1 Fabry disease is a rare genetic disorder that begins in childhood and is caused by a near-complete lack of the alpha-galactosidase A enzyme, leading to the buildup of fat in the body’s cells and organs. Various treatments are used, including enzyme replacement therapy, oral therapy, adjunct therapy, and other treatments. Diagnosis is done through methods such as blood tests, genetic tests, parenteral tests, and other diagnostic techniques. The various distribution channels include hospital pharmacies, online pharmacies, and retail pharmacies. These are used by various end users such as hospitals, homecare, specialty clinics, and other healthcare providers.

What Is The Fabry Disease Market Growth Forecast?

The fabry disease market size is expected to see strong growth in the next few years. It will grow to $3.27 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to advancement in gene-based therapies, expansion of newborn screening programs, increasing healthcare spending on rare diseases, growth in personalized medicine, development of next-generation oral therapies. Major trends in the forecast period include increasing adoption of enzyme replacement therapy, rising focus on rare disease diagnosis, growing use of genetic testing for early detection, expansion of oral and adjunct therapies, increasing patient-centric treatment approaches.

What Is The Driver Of The Fabry Disease Market?

A growing focus on personalized medicine is expected to propel the growth of the fabry disease market going forward. Personalized medicine is an approach to treatment that uses information about a person's genes, environment, and lifestyle to tailor medical care and therapies specifically to them for better outcomes. Rising focus on personalized medicine is driven by its ability to improve treatment effectiveness and reduce side effects by tailoring therapies to individual patient needs. Personalized medicine helps tailor treatment plans based on a patient’s specific genetic mutation and disease severity, improving outcomes and minimizing unnecessary side effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, In 2023, the FDA granted approval for 16 new personalized treatments for rare disease patients, marking a substantial increase from the six approvals in 2022. Therefore, a growing focus on personalized medicine drives the growth of the fabry disease industry.

Key Players In The Global Fabry Disease Market

Major companies operating in the fabry disease market are Sanofi S.A., GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, JCR Pharmaceuticals Co. Ltd., Sumitomo Pharma Co. Ltd, Chiesi Farmaceutici S.p.A., Amicus Therapeutics Inc., Idorsia Pharmaceuticals Ltd, Sangamo Therapeutics Inc., uniQure N.V., Protalix BioTherapeutics Inc., Spur Therapeutics Inc., Exegenesis Bio Inc., ISU ABXIS Co. Ltd., Eleva GmbH, AceLink Therapeutics Inc., 4D Molecular Therapeutics Inc., iBio Inc., Freeline Therapeutics Holdings plc, Greenovation Biotech GmbH

Global Fabry Disease Market Trends and Insights

Major companies operating in the fabry disease market are focusing on developing innovative therapies such as PEGylated enzyme replacement therapy (ERT) to enhance treatment efficacy, improve patient compliance, and reduce immunogenic responses associated with conventional ERTs. PEGylated enzyme replacement therapy (ERT) is a modified form of traditional ERT in which polyethylene glycol (PEG) chains are attached to the enzyme to increase its stability, prolong circulation time in the body, and reduce immune system reactions. For instance, in May 2023, Chiesi Global Rare Diseases, a division of the Chiesi Group, an Italy-based pharmaceutical company, announced the U.S. Food and Drug Administration (FDA), a US-based government agency approval for PRX-102 (pegunigalsidase alfa) for the treatment of adult Fabry disease patients. The approval is supported by a robust clinical program involving over 140 patients and long-term follow-up of up to 7.5 years, demonstrating the therapy’s efficacy in reducing renal Gb₃ deposits and maintaining kidney function while exhibiting a favorable safety profile.

What Are Latest Mergers And Acquisitions In The Fabry Disease Market?

In March 2024, Centogene N.V., a US-based rare disease diagnostics company, extended its strategic partnership with Takeda Pharmaceutical Company Limited, to continue providing access to genetic testing for patients with lysosomal storage disorders (LSDs). With this partnership extension, Centogene aims to enhance patient access to rapid and reliable diagnostic testing for LSDs including Fabry disease, Gaucher disease, and Hunter syndrome, leveraging its multiomic testing portfolio and diagnostic network to accelerate diagnoses and improve health outcomes for underserved rare disease patient communities. Takeda Pharmaceutical Company Limited is a Japan-based biopharmaceutical company specializing in rare disease therapeutics and enzyme replacement therapies including fabry disease.

What Defines the Fabry Disease Market?

The fabry disease market consists of revenues earned by entities by providing services such as genetic counseling, patient support programs, clinical trials and research services, and disease monitoring and management services. The market value includes the value of related goods sold by the service provider or contained within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Fabry Disease Market Report 2026?

The fabry disease market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the fabry disease industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.